-+ 0.00%
-+ 0.00%
-+ 0.00%

Tianjin Pharmaceutical announced that the company recently received the DMF First Medication Letter issued by the US FDA. The drug involved is betamethasone. The company submitted a betamethasone API application to the FDA in September 2019. Up to now, the project has invested about 3 million yuan in R&D. The letter indicates that the FDA has completed a scientific review of the DMF file for the company's betamethasone API, which can meet the ANDA reporting requirements of related formulation customers.

Zhitongcaijing·11/20/2026 07:49:20
Listen to the news
Tianjin Pharmaceutical announced that the company recently received the DMF First Medication Letter issued by the US FDA. The drug involved is betamethasone. The company submitted a betamethasone API application to the FDA in September 2019. Up to now, the project has invested about 3 million yuan in R&D. The letter indicates that the FDA has completed a scientific review of the DMF file for the company's betamethasone API, which can meet the ANDA reporting requirements of related formulation customers.